Skip to main content
Erschienen in: Current Rheumatology Reports 6/2015

01.06.2015 | Health Economics and Quality of Life (M Harrison, Section Editor)

How Important Is Mode of Administration in Treatments for Rheumatic Diseases and Related Conditions?

verfasst von: Nick Bansback, Logan Trenaman, Mark Harrison

Erschienen in: Current Rheumatology Reports | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Many new drugs do not offer clinical benefits over existing treatments but provide potentially more convenient modes of administration. These include how frequently a treatment is given, how it is delivered, who gives the treatment, and whether there are any associated local adverse reactions. We reviewed studies in rheumatology that ask patients and society the value they assign to these aspects of treatment in comparison to the benefits and side effects and costs. We find that mode of administration is generally valued by both patients and society, but the extent depends on the context of the disease and the study participants. Respondents with a more severe disease seem to assign less value to mode and frequency of administration, and prioritize improvement in pain and function. However, patients with chronic, but less severe, disease seem to place greater value on mode of administration. Furthermore, respondents with experience of the treatments perceived to be more inconvenient assigned lower value to more convenient treatments. Unfortunately, we found few examples of studies that reported values in a format that could easily be incorporated into resource allocation decisions by payers.
Literatur
1.
Zurück zum Zitat Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012;345:e4348.CrossRefPubMed Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012;345:e4348.CrossRefPubMed
4.
Zurück zum Zitat Singh JA, Christensen R, Wells G, Suarez-Almazor M, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Review). John Wiley & Sons; 2013. Singh JA, Christensen R, Wells G, Suarez-Almazor M, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Review). John Wiley & Sons; 2013.
6.
Zurück zum Zitat Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521.CrossRefPubMed Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521.CrossRefPubMed
7.
Zurück zum Zitat Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555–67.CrossRefPubMed Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555–67.CrossRefPubMed
8.
Zurück zum Zitat Louviere JJ, Woodworth G. Design and analysis of simulated consumer choice or allocation experiments: an approach based on aggregate data. J Mark Res. 1983;20:350–67.CrossRef Louviere JJ, Woodworth G. Design and analysis of simulated consumer choice or allocation experiments: an approach based on aggregate data. J Mark Res. 1983;20:350–67.CrossRef
9.
Zurück zum Zitat Green PE, Rao VR. Conjoint measurement for quantifying judgmental data. J Mark Res. 1971;8:355–63.CrossRef Green PE, Rao VR. Conjoint measurement for quantifying judgmental data. J Mark Res. 1971;8:355–63.CrossRef
10.
Zurück zum Zitat De Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21:145–72.CrossRefPubMed De Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21:145–72.CrossRefPubMed
11.
Zurück zum Zitat Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403–13.CrossRefPubMed Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403–13.CrossRefPubMed
12.
Zurück zum Zitat Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. Cambridge University Press; 2000. Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. Cambridge University Press; 2000.
13.
Zurück zum Zitat Mcfadden D. Conditional logit analysis of qualitative choice behavior. Front. Econom. New York: Academic; 1974. Mcfadden D. Conditional logit analysis of qualitative choice behavior. Front. Econom. New York: Academic; 1974.
14.
Zurück zum Zitat Darbà J, Restovic G, Kaskens L, Balbona MA, Carbonell A, Cavero P, et al. Patient preferences for osteoporosis in Spain: a discrete choice experiment. Osteoporos Int. 2011;22:1947–54.CrossRefPubMed Darbà J, Restovic G, Kaskens L, Balbona MA, Carbonell A, Cavero P, et al. Patient preferences for osteoporosis in Spain: a discrete choice experiment. Osteoporos Int. 2011;22:1947–54.CrossRefPubMed
15.
Zurück zum Zitat De Bekker-Grob EW, Essink-Bot M-L, Meerding WJ, Koes BW, Steyerberg EW. Preferences of GPs and patients for preventive osteoporosis drug treatment: a discrete-choice experiment. PharmacoEconomics. 2009;27:211–9.CrossRefPubMed De Bekker-Grob EW, Essink-Bot M-L, Meerding WJ, Koes BW, Steyerberg EW. Preferences of GPs and patients for preventive osteoporosis drug treatment: a discrete-choice experiment. PharmacoEconomics. 2009;27:211–9.CrossRefPubMed
17.
Zurück zum Zitat Fraenkel L, Gulanski B, Wittink DR. Preference for hip protectors among older adults at high risk for osteoporotic fractures. J Rheumatol. 2006;33:2064–8.PubMedCentralPubMed Fraenkel L, Gulanski B, Wittink DR. Preference for hip protectors among older adults at high risk for osteoporotic fractures. J Rheumatol. 2006;33:2064–8.PubMedCentralPubMed
19.
Zurück zum Zitat Hiligsmann M, Dellaert BG, Dirksen CD, van der Weijden T, Goemaere S, Reginster J-Y, et al. Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther. 2014;16:R36.CrossRefPubMedCentralPubMed Hiligsmann M, Dellaert BG, Dirksen CD, van der Weijden T, Goemaere S, Reginster J-Y, et al. Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther. 2014;16:R36.CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Laba T-L, Brien J, Fransen M, Jan S. Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS). BMC Musculoskelet Disord. 2013;14:160.CrossRefPubMedCentralPubMed Laba T-L, Brien J, Fransen M, Jan S. Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS). BMC Musculoskelet Disord. 2013;14:160.CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health. 2013;16:385–93.CrossRefPubMed Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health. 2013;16:385–93.CrossRefPubMed
22.
Zurück zum Zitat Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009;47:350–5.CrossRefPubMedCentralPubMed Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009;47:350–5.CrossRefPubMedCentralPubMed
23.
Zurück zum Zitat Harrison M, Marra C, Shojania K, Bansback N. Societal preferences for rheumatoid arthritis treatments. Evidence from a Discrete Choice Experiment. Rheumatology. In Press. Harrison M, Marra C, Shojania K, Bansback N. Societal preferences for rheumatoid arthritis treatments. Evidence from a Discrete Choice Experiment. Rheumatology. In Press.
24.
Zurück zum Zitat Özdemir S, Johnson FR, Hauber AB. Hypothetical bias, cheap talk, and stated willingness to pay for health care. J Health Econ. 2009;28:894–901.CrossRefPubMed Özdemir S, Johnson FR, Hauber AB. Hypothetical bias, cheap talk, and stated willingness to pay for health care. J Health Econ. 2009;28:894–901.CrossRefPubMed
25.
Zurück zum Zitat Poulos C, Hauber AB, González JM, Turpcu A. Patients’ willingness to trade off between the duration and frequency of rheumatoid arthritis treatments: patient preferences for RA treatments. Arthritis Care Res. 2014;66:1008–15.CrossRef Poulos C, Hauber AB, González JM, Turpcu A. Patients’ willingness to trade off between the duration and frequency of rheumatoid arthritis treatments: patient preferences for RA treatments. Arthritis Care Res. 2014;66:1008–15.CrossRef
26.
Zurück zum Zitat Fraenkel L, Suter L, Cunningham CE, Hawker G. Understanding preferences for disease-modifying drugs in osteoarthritis: preferences for disease-modifying drugs. Arthritis Care Res. 2014;66:1186–92.CrossRef Fraenkel L, Suter L, Cunningham CE, Hawker G. Understanding preferences for disease-modifying drugs in osteoarthritis: preferences for disease-modifying drugs. Arthritis Care Res. 2014;66:1186–92.CrossRef
27.
Zurück zum Zitat Burnett HF, Regier DA, Feldman BM, Miller FA, Ungar WJ. Parents’ preferences for drug treatments in juvenile idiopathic arthritis: a discrete choice experiment. Arthritis Care Res. 2012;64:1382–91.CrossRef Burnett HF, Regier DA, Feldman BM, Miller FA, Ungar WJ. Parents’ preferences for drug treatments in juvenile idiopathic arthritis: a discrete choice experiment. Arthritis Care Res. 2012;64:1382–91.CrossRef
28.
Zurück zum Zitat Cookson R. Willingness to pay methods in health care: a sceptical view. Health Econ. 2003;12:891–4.CrossRefPubMed Cookson R. Willingness to pay methods in health care: a sceptical view. Health Econ. 2003;12:891–4.CrossRefPubMed
29.
Zurück zum Zitat Harrison M, Rigby D, Vass C, Flynn T, Louviere J, Payne K. Risk as an attribute in discrete choice experiments: a systematic review of the literature. Patient-Patient-Centered Outcomes Res. 2014;1–20. Harrison M, Rigby D, Vass C, Flynn T, Louviere J, Payne K. Risk as an attribute in discrete choice experiments: a systematic review of the literature. Patient-Patient-Centered Outcomes Res. 2014;1–20.
31.
Zurück zum Zitat Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. 1st ed. USA: Oxford University Press; 1996. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. 1st ed. USA: Oxford University Press; 1996.
32.
Zurück zum Zitat Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–92.CrossRefPubMed Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–92.CrossRefPubMed
33.
Zurück zum Zitat EuroQol. EuroQol—a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy Amst Neth. 1990;16:199–208.CrossRef EuroQol. EuroQol—a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy Amst Neth. 1990;16:199–208.CrossRef
34.
Zurück zum Zitat Bansback N, Harrison M, Brazier J, Davies L, Kopec J, Marra C, et al. Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum. 2008;59:1018–26.CrossRefPubMed Bansback N, Harrison M, Brazier J, Davies L, Kopec J, Marra C, et al. Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum. 2008;59:1018–26.CrossRefPubMed
37.
38.
Zurück zum Zitat Donaldson C, Shackley P. Does “process utility” exist? A case study of willingness to pay for laparoscopic cholecystectomy. Soc Sci Med. 1997;44:699–707.CrossRefPubMed Donaldson C, Shackley P. Does “process utility” exist? A case study of willingness to pay for laparoscopic cholecystectomy. Soc Sci Med. 1997;44:699–707.CrossRefPubMed
39.
Zurück zum Zitat Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract. 2011;65:408–14.CrossRefPubMed Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract. 2011;65:408–14.CrossRefPubMed
40.
Zurück zum Zitat Wilson TD, Gilbert DT. Affective forecasting knowing what to want. Curr Dir Psychol Sci. 2005;14:131–4.CrossRef Wilson TD, Gilbert DT. Affective forecasting knowing what to want. Curr Dir Psychol Sci. 2005;14:131–4.CrossRef
Metadaten
Titel
How Important Is Mode of Administration in Treatments for Rheumatic Diseases and Related Conditions?
verfasst von
Nick Bansback
Logan Trenaman
Mark Harrison
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 6/2015
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0514-3

Weitere Artikel der Ausgabe 6/2015

Current Rheumatology Reports 6/2015 Zur Ausgabe

PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

Treat to Target in Psoriatic Arthritis—Evidence, Target, Research Agenda

Spondyloarthritis (MA Khan, Section Editor)

Revisiting MHC Genes in Spondyloarthritis

Orphan Diseases (B Manger, Section Editor)

Tumor-Induced Osteomalacia: an Up-to-Date Review

Orphan Diseases (B Manger, Section Editor)

Multicentric Reticulohistiocytosis: a Critical Review

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.